Pharmaceutical

argenx’s VYVDURA gains approval in Japan for gMG treatment

Japan has approved argenx’s VYVDURA injection for subcutaneous administration to treat generalised myasthenia gravis (gMG) in adults.

Jan 19, 2024 - 18:00
argenx’s VYVDURA gains approval in Japan for gMG treatment
Japan has approved argenx’s VYVDURA injection for subcutaneous administration to treat generalised myasthenia gravis (gMG) in adults.
Read the original article

Tags:

Previous Article

BridgeBio secures $1.25bn for genetic therapy development

Next Article

Synendos set to study endocannabinoid inhibitor for neuropsychiatric conditions

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Tyra Biosciences’ TYRA-300 gains FDA rare paediatric disease status

Tyra Biosciences’ TYRA-300 gains FDA rare paediatric di...

Feb 2, 2024

STAT+: HCA bags big first quarter as patient volumes soar

STAT+: HCA bags big first quarter as patient volumes soar

Apr 21, 2023

AstraZeneca, maker of FluMist, seeks to allow at-home administration of vaccine

AstraZeneca, maker of FluMist, seeks to allow at-home a...

Oct 24, 2023